Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

NCCN grants funding to five oncology leaders of the future

The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-announces the 2026 recipients for the annual NCCN Foundation® Young Investigator Awards.

2 Apr 2026

Popular vitamin B3 supplements could weaken cancer therapy effectiveness

Millions of Americans take daily supplements-nicotinamide mononucleotide (NMN), nicotinamide riboside (NR) and nicotinamide (NAM)-to boost energy, slow aging and protect the heart and brain.

1 Apr 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Gut-derived metabolites regulate immune cells in complex ways

Published on March 23, 2026, in Volume 2, article number 18 of the journal Immunity & Inflammation, the review begins by systematically outlining the sources and synthetic pathways of immune-relevant microbial metabolites, including bile acids, short-chain fatty acids, amino acid derivatives, vitamins, trimethylamine/trimethylamine N-oxide, and odd-chain fatty acids.

31 Mar 2026

Industry and academic leaders gather to accelerate new cancer cures

Damon Runyon scientists and industry partners gathered on Tuesday, March 24, for the 2026 Accelerating Cancer Cures Research Symposium, hosted by Amgen in Cambridge, Massachusetts.

27 Mar 2026

Molecular test shows high sensitivity in detecting bile duct cancer

When patients develop a narrowing or blockage in the bile ducts – the tubes connecting the liver, gallbladder and intestines – physicians must determine whether the cause is cancer or a benign condition.

27 Mar 2026

Obesity-driven organ enlargement may boost cancer risk

Scientists at City of Hope® and TGen (part of City of Hope) are the first to explain a major mechanism for why gaining excess weight increases your risk of cancer.

26 Mar 2026

New nanomaterial enhances bioimaging and targeted cancer drug delivery

The Nanomedicine and Nanotoxicology Group (GNano) at the University of São Paulo's São Carlos Institute of Physics (IFSC-USP) in Brazil has discovered a way to transform hydroxyapatite, a bioceramic material, into a nanoparticle with enhanced intrinsic luminescence.

18 Mar 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

Fertility treatments linked to small increases in some cancers

Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns with the general female population.

13 Mar 2026

Experimental therapy eliminates pancreatic precancerous cells in mice study

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

12 Mar 2026

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

Dual-positive hybrid cells linked to shorter survival in advanced breast cancer

An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

11 Mar 2026